Lidia Larrañaga. Qualified person / Regulatory affairs.

Ander Larrañaga. General Manager/ Business Development.

Giuseppe Tomasi Scianó.
R&D Manager.


A young company with mature knowledge.


At LITAPHAR we work on research into new indications that provide therapeutic solutions for illnesses related to women. Most of them not tackled until now.

More specifically, we have been researching for 12 years into different applications in gynaecology and obstetrics of prostaglandin analogues, progesterone receptor antagonists and selective modulators of progesterone receptors.

The Projects we are currently developing are:

  • Endometriosis
  • Uterine Fibroid
  • Postpartum Hemorrhage
  • Dysfunctional Uterine Hemorrhages
  • Labour Induction
  • Cervix Dilation
  • Voluntary Termination of Pregnancy
  • Emergency Contraception

At LITAPHAR we are a reference in the research into the health and quality of life of women and more specifically into sexuality and vulvar health.

We were pioneers examining different products for the female sexual dysfunctions based on L-Arginine.

In addition to products for vulvar hygiene and daily care, at LITAPHAR we never forget that good sexual health is based on good vaginal health and for this reason we create solutions for the following pathologies:

  • Vulvodynia
  • Vulvo-vaginitis
  • Atrophic vulvitis


At LITAPHAR we are supported by an extensive and effective network of collaborators. We analyse and treat new or other, already known, products that target pathologies that right now are poorly or not at all dealt with.

We maintain a close relationship with different doctors and opinion leaders from several countries, as well as with research centres, which enables us to be well-informed at all times about the demands of professionals and about the clinical novelties that arise.

After obtaining and processing this information, at LITAPHAR we analyse every therapeutic niche and use molecules that have already been approved for other pathologies, which are new from a scientific/medical point of view and are viable and interesting from an economic point of view.

Once we have analysed the product and proven its viability, LITAPHAR’s goal is to develop the corresponding dossier and achieve its approval.